THE recommended retail price for the 2.5mg Mounjaro Kwikpen (starting dose) has dropped to $285 per month, effective 1 Dec, announced Lilly Australia.
Patients previously paid anywhere from $350-$400 for the non-PBS listed 2.5mg auto-injector KwikPen.
The price to wholesalers has been aligned with the new RRP as of 25 Nov.
Mounjaro (tirzepatide) is indicted in adults for chronic weight management and the treatment of type 2 diabetes.
According to the Therapeutic Goods Administration (TGA), there is a shortage of Mounjaro vials that is expected to continue until late next year.
Patients affected by the shortage can use the KwikPen instead of the vials in the same dosage amount, or a temporarily approved overseas-registered product.
However, the products cannot be dispensed using a prescription for the vial presentation, and patients will need a new prescription.
The above article was sent to subscribers in Pharmacy Daily's issue from 02 Dec 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Dec 24
